

EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of *BAX*

Thomas Grimm, Sabine Schneider, Elisabeth Naschberger, Jürgen Huber, Eric Guenzi, Arnd Kieser, Peter Reitmeir, Thomas F. Schulz, Cindy A. Morris, and Michael Stürzl

Latent membrane protein 1 (LMP-1) of Epstein-Barr virus (EBV) promotes tumorigenesis by inhibiting apoptosis. We show that an important antiapoptotic activity of LMP-1 is the inhibition of Bcl2-associated protein X (Bax), a potent proapoptotic protein. BAX expression was regulated by LMP-1 activation of nuclear factor κ B (NF- κ B) via the C-terminal activation region 1 (CTAR-1) and CTAR-2. Interestingly, p65/p50 inhibited, whereas p50/p50 increased, BAX promoter activity as dem-

onstrated by overexpression and selective inhibition of these NF- κ B isoforms. Electrophoretic mobility shift analysis revealed that LMP-1 activates 2 of the 3 NF- κ B binding sites (κ B1- κ B3) in the BAX promoter. LMP-1 induced binding of the NF- κ B heterodimer p65/p50 to the κ B2 site and of the p50/p50 homodimer to the κ B3 site. Promoter mutation analysis revealed that the κ B2 site is necessary for inhibition of BAX promoter activity and the κ B3 site, for its activation. However,

the activation of the BAX promoter by LMP-1 was observed only in the presence of specific inhibitors of p65/p50. In all other cases, LMP-1 inhibited BAX promoter activity. Most importantly, the antiapoptotic activity of LMP-1 was considerably decreased in cells deficient for BAX. These results indicate that the inhibition of Bax may be an important antiapoptotic activity of LMP-1. (Blood. 2005;105:3263-3269)

© 2005 by The American Society of Hematology

Introduction

Epstein-Barr virus (EBV) latent infection is associated with malignancy.¹ The latent membrane protein 1 (LMP-1) encoded by EBV plays a potential key role in the pathogenesis of EBV-associated malignancies such as Hodgkin lymphoma² and nasopharyngeal carcinoma.³ The mechanisms by which LMP-1 affects tumorigenesis are not fully understood.

LMP-1 consists of 386 amino acids. Its carboxyterminal cytoplasmic domain contains 2 C-terminal activation regions (CTARs), CTAR-1 and CTAR-2. CTAR-1 binds to tumor necrosis factor (TNF) receptor-associated factors (TRAFs) through a PxQxT motif^{4,5}; whereas, CTAR-2 binds to the TNF receptor-associated death domain (TRADD) through the tyrosine residue at amino acid position 384 (Tyr384).⁶ Binding of LMP-1 to TRAF and TRADD initiates the formation of a signaling complex⁶⁻⁸ that leads to activation of the nuclear factor κ B (NF- κ B) and p38/mitogen-activated protein kinase (MAPK) signaling pathways.⁹⁻¹¹ In addition, LMP-1 activation of the Janus kinase (JNK) signaling pathway is mediated through CTAR-1 and CTAR-2.^{8,12,13} (Figure 2A).

Inhibition of apoptosis is a key feature of EBV tumorigenicity. LMP-1 inhibits apoptosis in latently EBV-infected cells.^{14,15} Inhibition of apoptosis in EBV-infected cells correlates with the induction of antiapoptotic factors such as Bcl-2, A20, and Bfl-1 by LMP-1.¹⁴⁻¹⁸ Since apoptosis is regulated through the balance of both proapoptotic and antiapoptotic genes,¹⁹ the mechanism by

which LMP-1 inhibits apoptosis in virally infected cells may involve the regulation of both pro- and antiapoptotic genes. Accordingly, Bcl-2 and Bfl-1, which are up-regulated by LMP-1, inhibit apoptosis by sequestration of the proapoptotic factor Bax (Bcl2-associated protein X).^{20,21} Additionally, decreased Bax levels have been observed in various tumors, including EBV-associated Hodgkin disease,²² and associated with poor prognosis in lung²³ and stomach carcinomas.²⁴ Inactivating mutations of *BAX* have been detected in tumors of the colon²⁵ and in EBV-negative Burkitt lymphomas.^{26,27} Collectively, these findings suggest that functional deactivation of *BAX* and/or inhibition of *BAX* expression may be involved in EBV-associated lymphomas.

Here, we show that LMP-1 inhibits the expression of *BAX* via NF- κ B p65/p50 signaling, and we provide evidence that *BAX* may be an important target of the antiapoptotic activity of LMP-1.

Materials and methods

Cells, plasmids, and inhibitory drugs

The cell lines DG-75,²⁶ EBV-negative Akata (an Akata subclone that has lost the virus and has been shown to be EBV negative²⁸), HeLa, and CHO were kept in RPMI 1640/10% fetal calf serum (FCS; Gibco-BRL,

From the University of Erlangen-Nürnberg, Department of Surgery, Division of Molecular and Experimental Surgery, Erlangen, Germany; the GSF-National Research Center for Environment and Health, Institute of Molecular Virology, Department of Virus-induced Vasculopathy, and the Institute of Health Economics and Health Care Management, Neuherberg, Germany; GSF-National Research Center for Environment and Health, Institute of Clinical Molecular Biology and Tumor Genetics, Department of Gene Vectors, Munich, Germany; Medical School Hannover, Department of Virology, Hannover, Germany; and Tulane University Health Service Center, Department of Microbiology and Immunology, New Orleans, LA.

Submitted July 19, 2004; accepted December 11, 2004. Prepublished online as *Blood* First Edition Paper, December 21, 2004; DOI 10.1182/blood-2004-07-2752.

Supported by grants of the Deutsche Forschungsgemeinschaft (DFG-SPP

1130), the Bavarian State Ministry of Sciences, Research and the Arts (Bavaria-Quebec Research Cooperation), the German Cancer Aid (Deutsche Krebshilfe, Apoptose-Schwerpunktprogramm), and the Interdisciplinary Center for Clinical Research (IZKF, projects A1 and B11) of the University of Erlangen to M.S.

Reprints: Michael Stürzl, University of Erlangen-Nürnberg, Department of Surgery, Division of Molecular and Experimental Surgery, Schwabachanlage 10, D-91054 Erlangen, Germany; e-mail: michael.stuerzl@chir.imed.uni-erlangen.de.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2005 by The American Society of Hematology

Karlsruhe, Germany); BC-1,²⁹ in RPMI 1640/20% FCS; and HEK 293-T, in DMEM/10% FCS. 1852.4 human B cells³⁰ were grown in RPMI 1640/10% tetracycline-free FCS (Clontech, Heidelberg, Germany) with 2 μ g/mL tetracycline.

The plasmids pSV2-CAT,³¹ pHIV-1-LTR-CAT,³² pro237-GPB-1,³³ pHEBo,³⁴ pHEBo-LMP-1 (pLMP-1) and its derivatives pLMP-1(PQT>AAA), pLMP-1(Y384G), pLMP-1(PQT>AAA/Y384G), and pLMP-1(Δ COOH),¹² and pIkB α (S32/36A)³⁵ were previously described. pBAX-CAT contains nucleotide (nt) -1416 to nt -317 relative to the translation start of the *BAX* gene including 3 κ B consensus sites at nts -702 to -693 (κ B1), -687 to -678 (κ B2), and -502 to -493 (κ B3).³⁶ pBAX-CATm- κ B2 and pBAX-CATm- κ B3 are mutants of pBAX-CAT, with the nucleotide exchanges described in "Electrophoretic mobility shift assay (EMSA)." pK15 contains a cDNA of human herpesvirus 8 (HHV-8) open reading frame (ORF) K15 encoding a 23-kDa product³⁷ in the expression vector pCDNA-3. Expression plasmids for p65, p50, and IRF-1 in pCMV-T³⁸ were provided by Dr John Hiscott (McGill University, Montreal, QC).

siRNA to p65, p50, and a sequence-scrambled control with previously published sequences^{39,40} were purchased from MWG Biotech (Ebersberg, Germany). The plasmid psi-BAX encoding siRNA to Bax was constructed by cloning the published siRNA sequence⁴¹ in the vector pSuppressorRetro (Biocarta, Hamburg, Germany). Accordingly, a sequence-scrambled control siRNA was cloned.

Caffeic acid phenethyl ester (CAPE; Calbiochem, Schwalbach, Germany), SN50 (Biomol, Hamburg, Germany), and Bay11-7082 (Calbiochem) were added daily at 5 μ g/mL, 100 μ g/mL, and 1 μ M, respectively.

Transfection

Adherent cells were transfected with Effectene (Qiagen, Hilden, Germany). Nonadherent cells were electroporated in 4-mm cuvettes in an Easyject (EquiBio, Maidstone, United Kingdom). Consistent transfection efficiency was monitored by cotransfection of pFRED encoding the green fluorescent protein (gift from Dr Severine Démart, GSF, Neuherberg, Germany).

CAT assays

At 3 days after transfection with the reporter plasmid containing the chloramphenicol-acetyltransferase (*CAT*) gene and the effector plasmid or the plain vector as a reference, cells were ruptured by freeze-thawing in 0.25 M Tris (tris(hydroxymethyl)aminomethane) HCl, pH 7.8. Equal amounts of protein were used in the standard CAT assay.⁴² The separated reaction products were quantitatively evaluated using a Storm 86 phosphorimager (Amersham-Pharmacia, Freiburg, Germany).

In each experiment, the fraction of acetylated products was expressed in percent of the acetylated products present in reference samples. Means and standard deviations were calculated from 3 independent experiments. The reference value was set to 100% and thus has no standard deviation.

Immunoblotting

Western blot analysis was carried out as previously described.^{43,44} Primary antibodies used were mouse anti-LMP-1 (1:400; CS1-4; Dakopatts, Hamburg, Germany), rabbit anti-Bax (1:1000; New England Biolabs, Frankfurt, Germany), anti-p50 and anti-p65 (both 1:1000; Santa Cruz, Heidelberg, Germany), and mouse anti-glyceraldehyde phosphate dehydrogenase (GAPDH, 1:20 000; Chemicon, Hofheim, Germany).

Electrophoretic mobility shift assay (EMSA)

EMSA was carried out as described.³³ Oligonucleotides had the sequences 5'-GCTGAGGTG(C)G(T)G(C)AGGCTTCAGCCCGGG-3' (w- κ B1), 5'-TTCAGCCCC(C)G(T)G(C)AATTCAGACTGCAG-3' (w- κ B2), and 5'-GCTGAGACG(T)G(C)GG(T)TATCTCTGGGCT-3' (w- κ B3). Nucleotide exchanges in m- κ B1, m- κ B2, and m- κ B3 are given in parentheses. Mutant sequences were obtained from Bentires-Alj et al³⁶; w- κ Bc (sc-2505) and m- κ Bc (sc-2511) were purchased from Santa Cruz. Experiments were repeated 3 times.

Flow cytometric apoptosis assay

Akata and DG-75 were treated for 24 hours with streptonigrin, fixed and permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen), and incubated for 30 minutes on ice with 5% fluorescein isothiocyanate (FITC)-anti-poly(ADP-ribose) polymerase (PARP) and 50% phycoerythrin-anti-LMP-1 antibody (both BD Pharmingen). Subsequently, cells were washed and fixed in 1% paraformaldehyde/phosphate-buffered saline (PBS). HEK 293-T cells were stained with the LIVE/DEAD Reduced Biohazard Cell Viability Kit no. 1 (Molecular Probes, Leiden, The Netherlands), which detects an apoptosis-related increase in cell membrane permeability, and were subsequently fixed. Fluorescence was determined using a FACScalibur (BD Pharmingen). Experiments were repeated 3 times.

Statistical analysis

Frequency of apoptosis was described by a generalized linear mixed model. We considered the classification parameters (1) streptonigrin (added or not), (2) cell type (Akata or DG-75; control-si or Bax-si), and type of LMP-1 (wild type or mutant) and assumed that the apoptosis event was binomially distributed. As variance components, the influences on individual samples were considered. Based on this model, adjusted frequencies as well as differences between cell type/LMP-1 type settings were calculated and statistically tested. Differences between the samples were transformed into odds ratios with 95% confidence intervals. $P < .05$ was considered statistically significant. All analyses were performed using the module GLIMMIX of the statistical software package SAS Version 8.2 (SAS, Heidelberg, Germany).

Results

LMP-1 inhibits *BAX* promoter activity

To determine whether LMP-1 regulates *BAX* promoter activity, transient expression assays using the reporter plasmid pBAX-CAT and a mammalian expression vector for LMP-1 were performed in various human cell lines (Akata [EBV-negative Burkitt lymphoma], BC-1 [HHV-8/EBV-infected peripheral effusion lymphoma], HEK 293-T [kidney]) and in Chinese hamster ovary (CHO) cells. In untransfected BC-1 cells, LMP-1 was not detectable by fluorescence-activated cell sorter (FACS) analysis (data not shown).

LMP-1 reduced relative levels of *BAX* promoter-directed CAT expression in all of the cells tested, suggesting that LMP-1 functionally inhibits *BAX* promoter activity (Figure 1A, lane 2; 1B, upper panels, black bars). Also, Western blot analysis confirmed that LMP-1 repressed the expression of Bax protein in transiently transfected HEK 293-T cells (data not shown). In contrast, a cDNA of the HHV-8 ORF K15 encoding a 23-kDa protein that has similarities to EBV LMP-1, but that does not activate the NF- κ B pathway,³⁷ did not affect *BAX* promoter-directed CAT expression in these cells (Figure 1A, lane 4; 1B, upper panels, gray bars).

Although LMP-1 inhibited *BAX* promoter activity, control experiments showed that LMP-1 activated the HIV-1-LTR (Figure 1A, lane 6) and the human *GBP-1* promoter (6.6-fold compared with basal activity; data not shown), which are both activated by NF- κ B.^{9,33} The activity of the *sv40* promoter (pSV2-CAT) was not affected by LMP-1 (Figure 1B, lower panels). These data indicated that LMP-1 selectively inhibits *BAX* promoter activity. In all cases, HHV-8 K15 failed to demonstrate a significant effect (Figure 1A lanes 4,8; 1B, lower panel, gray bars).

LMP-1 inhibits the expression of *BAX* in EBV-infected cells

To determine whether LMP-1 affects endogenous *BAX* expression, the B-cell line 1852.4 that is infected with a mini EBV and in which




Figure 1. LMP-1 inhibits *BAX* promoter activity and protein expression. (A) CAT assay of HEK 293-T cells cotransfected with pBAX-CAT (lanes 1-4) or pHIV-1-LTR-CAT (lanes 5-8) in combination with pHEBo (lanes 1,5), pLMP-1 (lanes 2,6), pcDNA-3 (lanes 3,7), or pK15 (lanes 4,8), or transfected with pHEBo only (lane 9). (B) Different cell lines were cotransfected with pBAX-CAT (top row) or pSV2-CAT (bottom row) and pLMP-1 (■), pK15 (□), or the control vectors (pHEBo for pLMP-1; pcDNA-3 for pK15; □). CAT activity in transfections with the control vector was set to 100% and compared with CAT activity in the presence of pLMP-1 and pK15. (C) Western blot analysis of LMP-1 (top), Bax (middle), and GAPDH (bottom) protein in 1852.4 cells. Cells were maintained in the absence of tetracycline for 7 days and subsequently 2 μ g/mL tetracycline was added for 6 days. DG75 cells that express neither LMP-1 nor Bax were used as a control (right lane). (D) 1852.4 cells were grown 6 days in the absence (-Tet, left) or presence (+Tet, right) of 2 μ g/mL tetracycline and transfected with pBAX-CAT (□) or pSV2-CAT (■). CAT activity was measured as described for panel B. (B,D) The means and standard deviations of 3 independent experiments are shown.

LMP-1 expression can be induced by tetracycline was used.³⁰ Cultivation of 1852.4 cells for 7 days in the absence of tetracycline caused a complete shut-off of LMP-1 protein expression (Figure 1C, day 0). After addition of tetracycline, LMP-1 expression increased constantly and reached plateau levels after 4 days as determined by Western blot analysis (Figure 1C, upper panel). Maximal LMP-1 expression in tetracycline-treated 1852.4 cells was comparable with that found in EBV-infected lymphoblastoid cell lines (data not shown; Kilger et al³⁰). Inversely to the increase of LMP-1, Bax protein expression decreased gradually and was almost undetectable at day 6 (Figure 1C, middle panel). As a control, DG-75 B cells that do not express LMP-1 and Bax were included (Figure 1C, last lane). Transient expression assays demonstrated that *BAX* promoter activity was less than 50% in LMP-1-expressing 1852.4 cells compared with 1852.4 cells in which LMP-1 expression was reduced by tetracycline withdrawal for 6 days (Figure 1D, white bars). The *sv40* promoter activity in 1852.4 cells was unaffected by tetracycline-induced expression of LMP-1 (Figure 1D, black bars).

CTAR-1 and CTAR-2 of LMP-1 cooperate in the inhibition of *BAX* promoter activity

To map the region in the LMP-1 protein that mediates inhibition of *BAX* promoter activity, LMP-1 mutants were expressed in HEK 293-T cells and their effect on *BAX* promoter activity was investigated. The LMP-1 mutants used included LMP-1(PQT>AAA), which has an inactivated CTAR-1; LMP-1(Y384G), which has an inactivated CTAR-2; and LMP-1(PQT>AAA/Y384G), which is mutated in both CTARs and LMP-1(Δ COOH) in which the entire carboxyterminal cytoplasmic region is deleted (Figure 2A). Western blot analysis confirmed the expression of wild-type and mutant LMP-1 proteins (Figure 2B). pLMP-1(Δ COOH) expression was not detected because the anti-LMP-1 antibody used is directed against the cytoplasmic moiety of LMP-1. *BAX* promoter activity was reduced to 50% of its normal level in wild-type LMP-1-expressing cells ($P = .0004$) and to 58% ($P = .0012$) and 72% ($P = .0185$) in LMP-1(PQT>AAA)- and LMP-1(Y384G)-expressing cells, respectively (Figure 2C, left). In cells that expressed LMP-1(PQT>AAA/Y384G) or LMP-1(Δ COOH), *BAX* promoter activity was not significantly reduced (Figure 2C, left). Neither LMP-1 nor any of its mutants had significant effects on the *sv40* promoter (Figure 2C, right). These results suggested that LMP-1 repressed *BAX* expression via the cooperative activity of CTAR-1 and CTAR-2 signaling motifs.




Figure 2. Mutations in CTAR-1 and CTAR-2 abrogate the inhibitory effect of LMP-1 on *BAX* promoter activity. (A) Schematic presentation of LMP-1 and LMP-1-activated signaling pathways. Alterations in mutated LMP-1 proteins are indicated (PQT > AAA, Y384G, Δ COOH). (B) HEK 293-T cells were cotransfected with plasmids encoding wild-type LMP-1 or various mutants of LMP-1 (see Figure 2A) and with pBAX-CAT. The expression of wild-type LMP-1 and the respective mutants was analyzed by Western blot. Detection of GAPDH was included as loading control. (C) Quantitative evaluation of CAT assay of HEK 293-T cells transfected with pBAX-CAT (left side) or pSV2-CAT (right side) and wild-type or mutant pLMP-1. Mean values and standard deviations of 3 independent experiments are shown; * $P < .05$.

LMP-1 inhibits *BAX* promoter activity via the NF- κ B signaling pathway

Since CTAR-1 and CTAR-2 are known to activate the NF- κ B signaling pathway,⁴ various inhibitors were used to determine whether LMP-1 inhibition of *BAX* promoter activity is mediated through NF- κ B. The NF- κ B inhibitors used include CAPE, which inhibits various forms of NF- κ B⁴⁵; SN50, which inhibits homodimers and heterodimers containing p50 (p65/p50, p50/p50)⁴⁶; and I κ B α (S32/36A), which selectively inhibits p65/p50,³⁵ but not p50/p50, activity.⁴⁷ Western blot analysis showed that LMP-1 expression in transfected HEK 293-T cells was not affected by these inhibitors (Figure 3A, upper panel, lanes 2,4,6,8). Interestingly, CAPE and SN50 abolished the inhibitory effect of LMP-1 on the *BAX* promoter, whereas, I κ B α (S32/36A) stimulated *BAX* promoter activity 1.7-fold in the presence of LMP-1 (Figure 3A, lower panel, black bars). This suggested that the different NF- κ B forms targeted by these inhibitors may exert opposite effects on *Bax* expression.

In order to investigate this, p65 and p50 were expressed in HEK 293-T cells in gradually changing ratios ranging from exclusive expression of p65 (Figure 3B, lane 2) toward exclusive expression of p50 (Figure 3B, lane 8). *BAX* promoter activity was significantly inhibited ($P < .001$) in cells that expressed predominantly p65/p50 after transfection with p65- and p50-encoding plasmids in 1:1 or 1:3 ratios (Figure 3B, lower panel, lanes 5-6); whereas, transfection of p50 plasmid alone or in a large excess to the p65 plasmid increased *BAX* promoter activity 2.9- and 1.6-fold ($P = .025$ and $P = .0968$), respectively (Figure 3B, lower panel, lanes 7-8). Interferon regulatory factor-1 (IRF-1) did not affect *BAX* promoter activity (Figure 3B, lower panel, lane 9). The HIV-1-LTR was activated by both p65/p50 and p50/p50 (Figure 3C). CAPE abrogated both the inhibition and the activation of *BAX* promoter activity in HEK 293-T cells that expressed ectopically p65/p50 and p50/p50 (Figure 3D, lanes 5-6). In contrast, pI κ B α (S32/36A) abolished only the inhibition of *BAX* promoter activity by p65/p50 (Figure 3D, lane 8) but not its activation by p50/p50 (Figure 3D, lane 9). Western blot analysis showed that CAPE and I κ B α (S32/36A) did not affect p65 and p50 protein expression (Figure 3D, upper panel).

Finally, siRNA was used to specifically inhibit p65 and p50 expression in HEK 293-T cells. Western blot revealed that overexpression of p65 (Figure 3E, middle) and p50 (Figure 3E, right) was specifically and efficiently inhibited by the respective p65 (p65-si) and p50 (p50-si) siRNAs, whereas a control siRNA (ctr-si) had no effect (Figure 3E). Analysis of *BAX* promoter activity in these cells showed that p65-si and p50-si applied together abolished the inhibitory effect of LMP-1 (Figure 3F, left panel, right columns) and p65-si increased *BAX* promoter activity to more than 200% (Figure 3F, left panel, middle columns). *sv40* promoter activity was unaffected by LMP-1 or by the various siRNAs (Figure 3F, right panel).

These results were confirmed in EBV-infected 1852.4 cells. Tetracycline-induced LMP-1 decreased *BAX* promoter activity to 50% (Figure 3G, left, black bar). This effect was abrogated by SN50 (Figure 3G, middle); whereas, in the presence of Bay11-7082, a specific inhibitor of p65/p50 that does not affect p50/p50,⁴⁸ *BAX* promoter activity was increased in these cells 2.5-fold (Figure 3G, right, black bar).

These results showed that LMP-1 activates both *BAX* inhibiting (p65/p50) and *BAX* activating (p50/p50) pathways of NF- κ B. In all cells tested, the *BAX* inhibiting pathway was predominant (com-




Figure 3. Inhibition of *BAX* promoter activity by LMP-1 is mediated by the NF- κ B pathway. (A) Western blot for LMP-1 (top) and CAT assay (bottom) of HEK 293-T cells cotransfected with pBAX-CAT and with pHEBo (□) or pLMP-1 (■) and with pcDNA-3 (columns 1-6) or pI κ B α (S32/36A) (columns 7-8) and grown in the presence of 5 μ g/mL CAPE (columns 3-4) or 100 μ g/mL SN50 (columns 5-6). (B) Detection of p65 and p50 protein expression by Western blot (top) and CAT assay (bottom) of HEK 293-T cells cotransfected with pBAX-CAT and the vector pCMV-T (lane 1) or pCMV-T-p65 and pCMV-T-p50 in gradually changing ratios but at constant total amount (0.3 μ g) (lanes 2-8) or with an IRF-1 expression plasmid (lane 9). *Significantly different from vector control ($P < .05$). (C) CAT assay as in panel B with pBAX-CAT replaced by pHIV-1-LTR-CAT. (D) Western blot for p65 and p50 expression (top) and CAT assay (bottom) of HEK 293-T cells cotransfected with pBAX-CAT and with vector pCMV-T (■), equal amounts of pCMV-T-p65 and pCMV-T-p50 (□), or pCMV-T-p50 alone (▨) and with pcDNA-3 (columns 1-6) or pI κ B α (S32/36A) (columns 7-9) and grown in the absence (columns 1-3, 7-9) or presence (columns 4-6) of 5 μ g/mL CAPE. (E) Western blot for p65 (top) and p50 (bottom) in HEK 293-T cells cotransfected with pBAX-CAT and pCMV-T (left), pCMV-T-p65 (middle), or pCMV-T-p50 (right) expression plasmids and control siRNA (ctr-si), p65-siRNA (p65-si), or p50-siRNA (p50-si). (F) CAT assay of HEK 293-T cotransfected with pBAX-CAT (left) or pSV2-CAT (right) together with pHEBo (□) or pLMP-1 (■) and with ctr-si, p65-si, or p65-si and p50-si. (G) CAT assay of 1852.4 cells grown 6 days in the absence (□) or presence (■) of 2 μ g/mL tetracycline, then transfected with pBAX-CAT and grown 3 days in the absence (left) or presence of 100 μ g/mL SN50 (middle) or 1 μ M Bay11-7082 (right). (A-D,F-G) CAT activity in control-transfected cells (first bar in each panel) was set to 100%. All experiments were performed in triplicate, and the mean and standard deviations are shown.

pare Figure 1B, D). *BAX* activation via p50/p50 was detected only in the presence of specific repressors of p65/p50 (Figure 3A,F-G).

LMP-1 inhibits *BAX* promoter activity via the κ B2 motif

The *BAX* promoter contains 3 κ B motifs (κ B1: -702 to -693; κ B2: -687 to -678; and κ B3: -502 to -493 relative to the translation start).³⁶ LMP-1-induced specific complexes at the κ B2 and κ B3 sites were detected by EMSA with nuclear extracts of




Figure 4. κ B2 of the *BAX* promoter is necessary for the inhibition of *BAX* promoter activity by LMP-1. (A) EMSA with κ B1, κ B2, and κ B3 wild-type and mutant oligonucleotides as probes without (–) or with nuclear extracts from 1852.4 cells grown 6 days in the absence (Tet–) or presence (Tet+) of 2 mg/mL tetracycline. LMP-1–dependent complexes are indicated by black arrows. An LMP-1–independent complex is indicated by a white arrow. (B) EMSA competition experiment with nuclear extracts of 1852.4 grown in the presence of tetracycline and radiolabeled wild-type κ B1, κ B2, and κ B3 oligos and an excess unlabeled κ B1, κ B2, κ B3, or κ B consensus region (κ Bc) wild-type (w) or mutant (m) oligonucleotides. (C) EMSA supershift analysis with κ B1, κ B2, and κ B3 oligonucleotides as probes and nuclear extracts of 1852.4 cells grown in the presence of tetracycline. Antibodies to p65, p50, and p52 were added to the binding reactions before incubation with the probe. Supershifted complexes are indicated by white (p65) and black (p50) arrows. (D) CAT assay of HEK 293-T cells cotransfected with reporter plasmids with wild-type (pBAX-CAT) or mutant *BAX* promoters (pBAX-CATm- κ B2 or pBAX-CATm- κ B3) and with pHEBo (□) or pLMP-1 (■). (E) CAT assay of HEK 293-T cells transfected with either pBAX-CAT, pBAX-CATm- κ B2, or pBAX-CATm- κ B3 in combination with either pCMV-T (□), pCMV-T-p50 (▨), or pCMV-T-p65 together with pCMV-T-p50 (■). (A–C) Representative example of 3 independent experiments. (D–E) CAT activity in the presence of the control vector was set to 100%. Mean and standard deviation of 3 independent experiments. * $P < .01$.

tetracycline-treated 1852.4 cells (Figure 4A, black arrows), whereas a complex at κ B1 appeared independently of LMP-1 (Figure 4A, white arrow). No complexes were detected with the mutated oligonucleotides (oligos) m- κ B1, m- κ B2, and m- κ B3 (Figure 4A). In addition, formation of these complexes was competed with an excess of unlabeled w- κ B1, w- κ B2, and w- κ B3 oligos, respectively (Figure 4B). The κ B2 and κ B3 complexes, but not the κ B1 complex, could also be competed with a consensus κ B oligo (κ Bc; Figure 4B). Supershift analyses demonstrated that the κ B2 complex contained both p65 (Figure 4C, middle, white arrow) and p50 (Figure 4C, middle, black arrow), whereas the κ B3 complex contained only p50 (Figure 4C, right, arrow). None of these proteins were detected in the κ B1 complex (Figure 4C, left).

To determine whether κ B2 and κ B3 are involved in inhibition of *BAX* gene expression by LMP-1, we investigated the activity of *BAX* promoters with mutations in κ B2 and κ B3 sites. While LMP-1 inhibited the wild-type promoter pBAX-CAT activity by 71% (Figure 4D, left, black bar), a promoter with a mutated κ B2 site (pBAX-CATm- κ B2) was not affected by LMP-1 (Figure 4D, middle). A promoter with a mutated κ B3 site (pBAX-CATm- κ B3) was inhibited by LMP-1 with almost the same efficiency as was wild-type pBAX-CAT (53%; Figure 4D, right, black bar). The predominant role of κ B2 in the inhibition of *BAX* expression was further supported by the finding that a promoter with a mutated κ B2 site failed to respond to overexpressed p65/p50 or p50/p50 (Figure 4E, middle). In contrast, a promoter with a mutated κ B3 was still inhibited by p65/p50 but was not activated by p50/p50 (Figure 4E, right). Altogether, these data suggested that binding of p65/p50 to κ B2 is sufficient for the inhibition of *BAX* expression,

whereas the up-regulation of *BAX* by p50/p50 requires both the κ B2 and κ B3 sites of the *BAX* promoter.

Inhibition of *BAX* is an important antiapoptotic function of LMP-1

Finally, to determine how the regulation of *BAX* expression affects the antiapoptotic activity of LMP-1, HEK 293-T cells that express *BAX*, *BCL-2*, and *BFL-1* (data not shown) were transfected with plasmids encoding Bax-siRNA (Figure 5B) or scrambled control-siRNA (Figure 5A). By Western blot analysis, we demonstrated that Bax protein expression is strongly decreased after transfection with Bax-siRNA in these cells (data not shown). In addition, the cells were transfected with pLMP-1 or the nonfunctional mutant pLMP-1 (PQT>AAA/Y384G) and with pGFP (green fluorescence) as a transfection marker. At 3 days after transfection, the cells were treated with 1 μ M of the DNA-damaging agent streptonigrin for 24 hours. Apoptosis-related changes in cell membrane permeability were detected with a specific dye (ethidium homodimer-2, red fluorescence). The relative numbers of apoptotic cells (red fluorescence) within the population of transfected cells (green fluorescence) were determined by FACS. In the absence of streptonigrin, the fraction of apoptotic cells was consistently less than 3% (Figure 5A–B, left; representative experiments are shown; mean values of 3




Figure 5. Bax is required for the antiapoptotic activity of LMP-1. (A–B) HEK 293-T cells were cotransfected with pGFP, with control-siRNA (A) or Bax-siRNA (B), and with mutant (top row) or wild-type (bottom row) LMP-1 and subsequently incubated with (right column) or without (left column) 1 μ M streptonigrin. After staining with Dead Red, cells were gated for pGFP expression by FACS analysis (horizontal axis), and the fraction of Dead Red–stained cells (vertical axis) within the transfected cells was determined. (C) Mean values and 95% confidence intervals (CI_{95}) of 3 experiments as in panels A–B; * $P < .05$. □ indicates control-si; ■, Bax-si. (D–E) Akata (D) and DG-75 (E) cells were transfected with mutant (top row) or wild-type (bottom row) LMP-1 and subsequently incubated with (right column) or without (left column) 0.25 μ M (Akata) or 1 μ M (DG-75) streptonigrin. After staining with FITC/anti-PARP and PE/anti-LMP-1, the expression of PARP (horizontal axis) within the fraction of LMP-1–positive cells (vertical axis) was assayed. (F) Mean values and CI_{95} intervals of 3 experiments as in panels D–E. * $P < .05$; ** $P < .001$; n.s. indicates not significant. □ indicates Akata; ■, DG-75. (A–B, D–E) Numbers show the fractions of apoptotic cells within the gate of transfected cells in the experiment shown; numbers in parentheses refer to the mean of 3 experiments.

independent experiments are given in parentheses and are displayed with confidence intervals in Figure 5C). In contrast, a high fraction (72.2%) of cells transfected with control-siRNA and mutant LMP-1 was apoptotic after streptonigrin treatment (Figure 5A, upper right panel). Of note, cells transfected with control-siRNA and wild-type LMP-1 were significantly ($P < .05$; odds ratio [OR] = 3.73; Figure 5C) less susceptible to apoptosis (41.0%; Figure 5A, lower right panel). The same decrease of apoptotic cells was observed in streptonigrin-treated HEK 293-T cells transfected with Bax-siRNA independent of the expression of mutant or wild-type LMP-1 (42.0% each; Figure 5B, right). These results were significantly different from those obtained with cells transfected with control-siRNA and expressing mutant LMP-1 ($P < .01$ and $P < .05$, respectively; OR = 3.58 for both; Figure 5C). These results demonstrated that the antiapoptotic activity of LMP-1 is absent in HEK 293-T cells with impaired *BAX* expression.

To confirm these results in B cells, LMP-1 antiapoptotic activity was analyzed in Akata cells that have a functional *BAX* gene (Figure 5D) and in DG-75 cells that have inactivating mutations in both *BAX* alleles²⁶ (Figure 5E). Western blot analysis confirmed that DG-75 cells did not express *BAX* (Figure 1C) but did express *BCL-2* and *BFL-1*, whereas, Akata cells expressed *BAX*, *BCL-2*, and *BFL-1* (data not shown). Akata and DG-75 cells were transfected with expression plasmids encoding either wild-type or mutant LMP-1. Subsequently, these cells were treated with streptonigrin in concentrations that induce similar rates of apoptosis (about 25%) in mutant LMP-1 transfectants (Akata: 0.25 μ M; DG-75: 1 μ M). To exclude assay-specific artifacts, a proteolytic fragment of PARP was used as an alternative indicator of apoptosis in these experiments. The fraction of apoptotic cells within the gate of LMP-1-positive cells was quantitatively determined by FACS analysis (Figure 5D-F).

In Akata and DG-75 cells expressing mutant and wild-type LMP-1, the fractions of apoptotic cells were below 6.6% (Figure 5D-E, left panels). After treatment with streptonigrin, a large fraction of the Akata cells with mutant LMP-1 were apoptotic (22.8%), whereas in cells with wild-type LMP-1 the fraction of apoptotic cells was only slightly increased (9.3%; Figure 5D, right panels). These values differed significantly ($P < .001$; OR = 2.86; Figure 5F). In contrast, the apoptotic fractions in mutant and wild-type LMP-1-transfected DG-75 cells differed only slightly (25.0% versus 18.0%; not significant; Figure 5F). These results demonstrated that, in B cells, Bax is also an important target of the antiapoptotic activity of LMP-1.

Discussion

Here, we showed that EBV LMP-1 inhibits *BAX* promoter activity in all 5 of the different cell lines used. The inhibition of *BAX* promoter activity was mediated cooperatively by CTAR-1 and -2 of LMP-1 as demonstrated by ectopic expression of LMP-1 mutants. Interestingly, previous studies have demonstrated that CTAR-1 and -2 cooperatively activate the NF- κ B signaling pathway,⁴ that the *BAX* promoter harbors 3 κ B consensus sites (κ B1- κ B3),³⁶ and that *BAX* expression is regulated by NF- κ B.^{36,49-51} Collectively, these findings suggested that LMP-1 may regulate *BAX* expression via NF- κ B signaling.

This was confirmed by analysis of LMP-1 effects on *BAX* promoter activity in the presence of inhibitors of different NF- κ B isoforms. CAPE or SN50 treatment of cells, or simultaneous transfection of p65 and p50-siRNA that targeted both p65/p50 and p50/p50, abrogated the effect of LMP-1 on *BAX* promoter activity. However, I κ B α (S32/36A) and p65-si RNA that selectively inhibited p65/p50, but not p50/p50,

activated *BAX* promoter activity in the presence of LMP-1. These results suggested that LMP-1 activates both p65/p50 and p50/p50, but p65/p50 inhibits and p50/p50 increases *BAX* promoter activity. Consistently, overexpression of p65/p50 inhibited *BAX* promoter activity, while the *BAX* promoter was activated by overexpressed p50/p50 (Figure 3B). This was in agreement with previous reports suggesting that an I κ B α -sensitive NF- κ B pathway may inhibit Bax expression^{36,49} and an I κ B α -insensitive NF- κ B pathway may activate Bax expression.^{50,51}

We showed by 2 approaches that the κ B2 and κ B3 consensus sites of the *BAX* promoter regulated the differential responses to the different NF- κ B isoforms. First, EMSA demonstrated that in LMP-1-expressing cells the κ B2 element forms a complex with p65/p50, whereas the κ B3 element binds to p50/p50 (Figure 4A-C). Binding of p65/p50 to κ B2 has also been shown by others.³⁶ Second, promoter mutation analyses clarified the functional role of the 2 κ B sites in the *BAX* promoter response to LMP-1. The κ B2 site was found to be key for the inhibitory effect of LMP-1 on *BAX* promoter activity, whereas the κ B3 element regulated the activation of the *BAX* promoter by p50/p50. However, in LMP-1-expressing cells the latter effect was observed only when an excess of p50/p50 was experimentally induced by specific inhibitors of p65/p50 (Figure 3D,F-G). Otherwise, in all of the different cell types investigated in this study, the predominant effect of LMP-1 was the inhibition of the *BAX* promoter by p65/p50.

As yet, it was known that LMP-1 can exert antiapoptotic activity by up-regulation of the expression of *BCL-2*, *BFL-1*, and *A20*.¹⁴⁻¹⁸ We showed that LMP-1, in addition, inhibits *BAX* promoter activity and that in cells with impaired *BAX* function or expression the antiapoptotic activity of LMP-1 is significantly reduced. The latter showed that Bax is an important target of the antiapoptotic activity of LMP-1. This is consistent with the fact that both Bcl-2 and Bfl-1 also inhibit apoptosis by sequestration and inactivation of Bax.^{20,21}

Altogether our results indicate that LMP-1 in latently EBV-infected cells activates 2 antiapoptotic defense mechanisms converging on Bax. First, LMP-1 inhibits *BAX* promoter activity. Second, LMP-1 activates the expression of *BCL-2*¹⁵ and *BFL-1*,¹⁸ which are potent inhibitors of Bax. The latter may neutralize residual Bax activity when inhibition of the *BAX* promoter is not sufficiently achieved. The relative contributions of both mechanisms may vary in different cell types.

Most importantly, our data suggest that the opposite effects of LMP-1 on *BAX* promoter activity mediated by p65/p50 and p50/p50 may be of clinical relevance. Specific inhibition of p65/p50 may result in activation of the *BAX* promoter via p50/p50 in the presence of LMP-1. This may render LMP-1-expressing cells more sensitive to apoptosis-inducing drugs in the therapy of EBV-related tumors and in other tumors in which NF- κ B is constitutively activated. On the other hand, the selective inhibition of p50/p50 may increase the antiapoptotic effect of LMP-1 on *BAX* expression and may exacerbate tumorigenesis.

Acknowledgments

We thank Dr Graham Packham, University of Southampton, Southampton, United Kingdom, for providing DG-75 cells; Dr John Hiscott, Mc Gill University, Montreal, QC, for p65, p50, and IRF-1 expression plasmids; Dr Michael Nüsse, Flow Cytometry Unit, GSF, Neuherberg, Germany, for help with the flow cytometric assays; and Dr Wolfgang Hammerschmidt, Institute of Clinical Molecular Biology and Tumor Genetics, GSF, Munich, Germany, for helpful discussions.

References

- Crawford DH. Biology and disease associations of Epstein-Barr virus. *Philos Trans R Soc Lond B Biol Sci*. 2001;356:461-473.
- Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. *Proc Natl Acad Sci U S A*. 1991;88:4766-4770.
- Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. *Int J Cancer*. 1988;42:329-338.
- Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. *J Virol*. 1998;72:7900-7908.
- Farrell PJ. Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. *Trends Microbiol*. 1998;6:175-178.
- Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. *Proc Natl Acad Sci U S A*. 1997;94:12592-12597.
- Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. *Cell*. 1996;84:299-308.
- Kieser A, Kaiser C, Hammerschmidt W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. *EMBO J*. 1999;18:2511-2521.
- Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. *J Virol*. 1992;66:6496-6501.
- Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. *J Biol Chem*. 1999;274:16085-16096.
- Schultheiss U, Puschner S, Kremmer E, et al. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. *EMBO J*. 2001;20:5678-5691.
- Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. *EMBO J*. 1997;16:6478-6485.
- Eliopoulos AG, Waites ER, Blake SM, Davies C, Murray P, Young LS. TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. *J Virol*. 2003;77:1316-1328.
- Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. *Nature*. 1991;349:612-614.
- Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. *Cell*. 1991;65:1107-1115.
- Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. *Science*. 1984;226:1097-1099.
- Laherty CD, Hu HM, Opiari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. *J Biol Chem*. 1992;267:24157-24160.
- D'Souza B, Rowe M, Walls D. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. *J Virol*. 2000;74:6652-6658.
- Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. *Semin Cancer Biol*. 1993;4:327-332.
- Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channel-forming activity by Bcl-2. *Science*. 1997;277:370-372.
- Zhang H, Cowan-Jacob SW, Simonen M, Greenhalf W, Heim J, Meyhack B. Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells. *J Biol Chem*. 2000;275:11092-11099.
- Lauritzen AF, Moller PH, Nedergaard T, Guldborg P, Hou-Jensen K, Ralfkiaer E. Apoptosis-related genes and proteins in Hodgkin's disease. *APMIS*. 1999;107:636-644.
- Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. *Am J Pathol*. 1996;149:1941-1952.
- Krajewska M, Fenoglio-Preiser CM, Krajewski S, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. *Am J Pathol*. 1996;149:1449-1457.
- Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science*. 1997;275:967-969.
- Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. *Oncogene*. 1998;16:1803-1812.
- Gutierrez MI, Cherney B, Hussain A, et al. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. *Cancer Res*. 1999;59:696-703.
- Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. *J Virol*. 1994;68:6069-6073.
- Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, Chang Y. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. *Blood*. 1995;86:2708-2714.
- Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. *EMBO J*. 1998;17:1700-1709.
- Bergsma DJ, Grichnik JM, Gossett LM, Schwartz RJ. Delimitation and characterization of cis-acting DNA sequences required for the regulated expression and transcriptional control of the chicken skeletal alpha-actin gene. *Mol Cell Biol*. 1986;6:2462-2475.
- Phares W, Franza BR Jr, Herr W. The kappa B enhancer motifs in human immunodeficiency virus type 1 and simian virus 40 recognize different binding activities in human Jurkat and H9 T cells: evidence for NF-kappa B-independent activation of the kappa B motif. *J Virol*. 1992;66:7490-7498.
- Naschberger E, Werner T, Vicente AB, et al. Nuclear factor-kappaB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells. *Biochem J*. 2004;379:409-420.
- Sugden B, Marsh K, Yates J. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. *Mol Cell Biol*. 1985;5:410-413.
- Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. *EMBO J*. 1995;14:2876-2883.
- Bentires-Alj M, Dejaridin E, Viatour P, et al. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. *Oncogene*. 2001;20:2805-2813.
- Brinkmann MM, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz TF. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. *J Virol*. 2003;77:9346-9358.
- Algarte M, Nguyen H, Heylbroeck C, Lin R, Hiscott J. I kappa B-mediated inhibition of virus-induced beta interferon transcription. *J Virol*. 1999;73:2694-2702.
- Zhou A, Scoggins S, Gaynor RB, Williams NS. Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. *Oncogene*. 2003;22:2054-2064.
- Laderach D, Compagno D, Danos O, Vainchenker W, Galy A. RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells. *J Immunol*. 2003;171:1750-1757.
- Bidere N, Lorenzo HK, Carmona S, et al. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. *J Biol Chem*. 2003;278:31401-31411.
- Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual*. 2nd ed. Cold Spring Harbor, NY: CSHL Press; 1989.
- Guenzi E, Töpolt K, Cornali E, et al. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. *EMBO J*. 2001;20:5568-5577.
- Guenzi E, Töpolt K, Lubeseder-Martellato C, et al. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. *EMBO J*. 2003;22:3772-3782.
- Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BS. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. *Proc Natl Acad Sci U S A*. 1996;93:9090-9095.
- Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. *J Biol Chem*. 1995;270:14255-14258.
- Malek S, Huxford T, Ghosh G. I kappa B Alpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappaB. *J Biol Chem*. 1998;273:25427-25435.
- Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced I kappa Balpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. *J Biol Chem*. 1997;272:21096-21103.
- Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. *Mol Cell Biol*. 1999;19:3485-3495.
- Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. *Nat Med*. 2001;7:1291-1297.
- Shou Y, Li N, Li L, Borowitz JL, Isom GE. NF-kappaB-mediated up-regulation of Bcl-X(S) and Bax contributes to cytochrome c release in cyanide-induced apoptosis. *J Neurochem*. 2002;81:842-852.



blood[®]

2005 105: 3263-3269
doi:10.1182/blood-2004-07-2752 originally published online
December 21, 2004

EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of *BAX*

Thomas Grimm, Sabine Schneider, Elisabeth Naschberger, Jürgen Huber, Eric Guenzi, Arnd Kieser, Peter Reitmeir, Thomas F. Schulz, Cindy A. Morris and Michael Stürzl

Updated information and services can be found at:
<http://www.bloodjournal.org/content/105/8/3263.full.html>

Articles on similar topics can be found in the following Blood collections

[Gene Expression](#) (1086 articles)
[Immunobiology](#) (5497 articles)
[Neoplasia](#) (4182 articles)
[Oncogenes and Tumor Suppressors](#) (795 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>